(NASDAQ: SLDB) Solid Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.77%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.92%.
Solid Biosciences's earnings in 2026 is -$174,325,000.On average, 14 Wall Street analysts forecast SLDB's earnings for 2026 to be -$204,358,759, with the lowest SLDB earnings forecast at -$275,289,057, and the highest SLDB earnings forecast at -$153,933,211. On average, 9 Wall Street analysts forecast SLDB's earnings for 2027 to be -$195,887,267, with the lowest SLDB earnings forecast at -$244,236,759, and the highest SLDB earnings forecast at -$157,032,537.
In 2028, SLDB is forecast to generate -$117,016,790 in earnings, with the lowest earnings forecast at -$163,919,929 and the highest earnings forecast at -$44,423,678.